Skip to main content Accessibility help

We use cookies to distinguish you from other users and to provide you with a better experience on our websites. Close this message to accept cookies or find out how to manage your cookie settings.

Close cookie message
×
Hostname: page-component-77c89778f8-fv566 Total loading time: 0 Render date: 2024-07-21T08:26:28.038Z Has data issue: false hasContentIssue false

14 - Relapsed acute lymphoblastic leukemia

from Section 3 - Evaluation and treatment

Published online by Cambridge University Press:  05 April 2013

By
Günter Henze  and
Arend von Stackelberg
Edited by
Ching-Hon Pui
Ching-Hon Pui
Affiliation:
St Jude's Children's Research Hospital
Get access

Summary

Introduction

With current treatment, 5-year event-free survival (EFS) rates in acute lymphoblastic leukemia (ALL) ranges between 75% and 80%. Therefore, relapse of ALL is still frequent, with an incidence range similar to that of neuroblastoma. Problems in the management of ALL relapse are the drug resistance of the leukemic cells and the reduced tolerance of patients to a second round of treatment after having already received intensive frontline therapy, resulting in a lower remission rate as well as a higher incidence of relapse and an inferior outcome overall.

Intensified polychemotherapy is essential for induction of a second complete remission (CR). Depending on a variety of prognostic factors, remission may be maintained with chemotherapy with or without cranial irradiation or with intensification of treatment by stem cell transplantation (SCT).

Diagnosis of relapse

The diagnosis of ALL relapse (i.e., the reappearance of leukemic cells in any anatomic compartment following CR) must be unequivocal. he workup includes a careful physical examination as well as investigations of the bone marrow (BM), the cerebrospinal luid (CSF) and, if necessary, biopsies of other involved sites (e.g., the testicles, lymph nodes, or any other organs or tissues).As at initial diagnosis, the leukemic cells have to be characterized morphologically and by immunophenotyping, as well as by cytogenetic and molecular genetic procedures. Only this comprehensive information, together with clinical findings, allows one to classify the leukemic subtype adequately and to assess the prognosis of individual patients.

Type
Chapter
Information
Childhood Leukemias , pp. 367 - 382
Publisher: Cambridge University Press
Print publication year: 2012

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Mitchell, C, Richards, S, Harrison, CJ, Eden, T. Long-term follow-up of the United Kingdom medical research council protocols for childhood acute lymphoblastic leukaemia, 1980–2001. Leukemia 2010;24:406–418.CrossRefGoogle ScholarPubMed
Moricke, A, Zimmermann, M, Reiter, A, et al. Long-term results of five consecutive trials in childhood acute lymphoblastic leukemia performed by the ALL-BFM study group from 1981 to 2000. Leukemia 2009;24: 265–284.CrossRefGoogle Scholar
Gaynon, PS.Childhood acute lymphoblastic leukaemia and relapse. Br J Haematol 2005;131:579–587.CrossRefGoogle ScholarPubMed
Henze, G.Chemotherapy for relapsed childhood acute lymphoblastic leukemia. Int J Pediatr Hematol Oncol 1997;5:199–213.Google Scholar
Bennett, JM, Catovsky, D, Daniel, MT, et al. Proposals for the classification of the acute leukaemias. French–American–British (FAB) co-operative group. Br J Haematol 1976;33:451–458.CrossRefGoogle ScholarPubMed
Loeffler, H, Gassmann, W. Morphology and cytochemistry of acute lymphoblastic leukaemia. Baillieres Clin Haematol 1994;7:263–272.CrossRefGoogle Scholar
Burger, B, Zimmermann, M, Mann, G, et al. Diagnostic cerebrospinal fluid examination in children with acute lymphoblastic leukemia: significance of low leukocyte counts with blasts or traumatic lumbar puncture. J Clin Oncol 2003;21:184–188.CrossRefGoogle ScholarPubMed
Wolfrom, C, Hartmann, R, Brühmüller, S, et al. Similar outcome on boys with isolated and combined testicular acute lymphoblastic leukemia relapse after stratified BFM salvage therapy. Haematol Blood Transfus 1997;38:647–651.Google Scholar
Steward, CG, Goulden, NJ, Katz, F, et al. A polymerase chain reaction study of the stability of Ig heavy-chain and T-cell receptor delta gene rearrangements between presentation and relapse of childhood B-lineage acute lymphoblastic leukemia. Blood 1994;83:1355–1362.Google ScholarPubMed
Vora, A, Frost, L, Goodeve, A, et al. Late relapsing childhood lymphoblastic leukemia. Blood 1998;92:2334–2337.Google ScholarPubMed
Lo Nigro, L, Cazzaniga, G, Di Cataldo, A, et al. Clonal stability in children with acute lymphoblastic leukemia (ALL) who relapsed five or more years after diagnosis. Leukemia 1999;13:190–195.CrossRefGoogle ScholarPubMed
Buehrer, C, Hartmann, R, Fengler, R, et al. Peripheral blast counts at diagnosis of late isolated bone marrow relapse of childhood acute lymphoblastic leukemia predict response to salvage chemotherapy and outcome. J Clin Oncol 1996;14:2812–2817.CrossRefGoogle Scholar
Eckert, C, Biondi, A, Seeger, K, et al. Prognostic value of minimal residual disease in relapsed childhood acute lymphoblastic leukaemia. Lancet 2001;358:1239–1241.CrossRefGoogle ScholarPubMed
Coustan-Smith, E, Gajjar, A, Hijiya, N, et al. Clinical significance of minimal residual disease in childhood acute lymphoblastic leukemia after first relapse. Leukemia 2004;18:499–504.CrossRefGoogle ScholarPubMed
Seeger, K, Stackelberg, AV, Taube, T, et al. Relapse of TEL-AML1-positive acute lymphoblastic leukemia in childhood: a matched-pair analysis. J Clin Oncol 2001;19:3188–3193.CrossRefGoogle ScholarPubMed
Kaspers, GJ, Wijnands, JJ, Hartmann, R, et al. Immunophenotypic cell lineage and in vitro cellular drug resistance in childhood relapsed acute lymphoblastic leukaemia. Eur J Cancer 2005;41:1300–1303.CrossRefGoogle ScholarPubMed
Gaynon, PS, Qu, RP, Chappell, RJ, et al. Survival after relapse in childhood acute lymphoblastic leukemia: Impact of site and time to first relapse: the Children's Cancer Group Experience. Cancer 1998;82:1387–1395.3.0.CO;2-1>CrossRefGoogle ScholarPubMed
Miniero, R, Saracco, P, Pastore, G, et al. Relapse after first cessation of therapy in childhood acute lymphoblastic leukemia: a 10-year follow-up study. Italian Association of Pediatric Hematology-Oncology (AIEOP). Med Pediatr Oncol 1995;24:71–76.CrossRefGoogle Scholar
Childhood, ALLCollaborative, Group. Duration and intensity of maintenance chemotherapy in acute lymphoblastic leukaemia: overview of 42 trials involving 12 000 randomised children. Lancet 1996;347:1783–1788.Google Scholar
Schroeder, H, Garwicz, S, Kristinsson, J, et al. Outcome after first relapse in children with acute lymphoblastic leukemia: a population-based study of 315 patients from the Nordic Society of Pediatric Hematology and Oncology (NOPHO). Med Pediatr Oncol 1995;25:372–378.CrossRefGoogle Scholar
Wheeler, K, Richards, S, Bailey, C, Chessells, J. Comparison of bone marrow transplant and chemotherapy for relapsed childhood acute lymphoblastic leukaemia: The MRC UKALL X experience. Medical Research Council Working Party on Childhood Leukaemia. Br J Haematol 1998;101:94–103.CrossRefGoogle ScholarPubMed
Kuo, AH, Yataganas, X, Galicich, JH, Fried, J, Clarkson, BD. Proliferative kinetics of central nervous system (CNS) leukemia. Cancer 1975;36:232–239.Google ScholarPubMed
Tsuchiya, J, Moteki, M, Shimano, S, et al. Proliferative kinetics of the leukemic cells in meningeal leukemia. Cancer 1978;42:1255–1262.3.0.CO;2-M>CrossRefGoogle ScholarPubMed
Jahnukainen, K, Saari, T, Salmi, TT, Pollanen, P, Pelliniemi, LJ. Reactions of Leydig cells and blood vessels to lymphoblastic leukemia in the rat testis. Leukemia 1995;9:908–914.Google ScholarPubMed
Henze, G, Fengler, R, Hartmann, R, et al. Six-year experience with a comprehensive approach to the treatment of recurrent childhood acute lymphoblastic leukemia (ALL-REZ BFM 85). A relapse study of the BFM Group. Blood 1991;78:1166–1172.Google ScholarPubMed
Buchanan, GR, Boyett, JM, Pollock, BH, et al. Improved treatment results in boys with overt testicular relapse during or shortly after initial therapy for acute lymphoblastic leukemia. A Pediatric Oncology Group study. Cancer 1991;68:48–55.3.0.CO;2-X>CrossRefGoogle ScholarPubMed
Ribeiro, RC, Rivera, GK, Hudson, M, et al. An intensive re-treatment protocol for children with an isolated CNS relapse of acute lymphoblastic leukemia. J Clin Oncol 1995;13:333–338.CrossRefGoogle ScholarPubMed
Winick, NJ, Smith, SD, Shuster, J, et al. Treatment of CNS relapse in children with acute lymphoblastic leukemia: a Pediatric Oncology Group study. J Clin Oncol 1993;11:271–278.CrossRefGoogle ScholarPubMed
Lal, A, Kwan, E, al Mahr, M, et al. Molecular detection of acute lymphoblastic leukaemia in boys with testicular relapse. Mol Pathol 1998;51:277–281.CrossRefGoogle ScholarPubMed
Neale, GA, Pui, CH, Mahmoud, HH, et al. Molecular evidence for minimal residual bone marrow disease in children with ‘isolated’ extra-medullary relapse of T-cell acute lymphoblastic leukemia. Leukemia 1994;8:768–775.Google ScholarPubMed
Hagedorn, N, Acquaviva, C, Fronkova, E, et al. Submicroscopic bone marrow involvement in isolated extramedullary relapses in childhood acute lymphoblastic leukemia: a more precise definition of “isolated” and its possible clinical implications, a collaborative study of the Resistant Disease Committee of the International BFM study group. Blood 2007;110:4022–4029.CrossRefGoogle ScholarPubMed
Bruggemann, M, Schrauder, A, Raff, T, et al. Standardized MRD quantification in European ALL trials: proceedings of the Second International Symposium on MRD assessment, Kiel, 18–20 September 2008. Leukemia 2010;24:521–535.CrossRefGoogle ScholarPubMed
van der Velden, VH, Cazzaniga, G, Schrauder, A, et al. Analysis of minimal residual disease by Ig/TCR gene rearrangements: guidelines for interpretation of real-time quantitative PCR data. Leukemia 2007;21:604–611.CrossRefGoogle ScholarPubMed
Campana, D, Coustan-Smith, E. Advances in the immunological monitoring of childhood acute lymphoblastic leukaemia. Best Pract Res Clin Haematol 2002;15:1–19.CrossRefGoogle ScholarPubMed
Buehrer, C, Hartmann, R, Fengler, R, et al. Superior prognosis in combined compared to isolated bone marrow relapses in salvage therapy of childhood acute lymphoblastic leukemia. Med Pediatr Oncol 1993;21:470–476.CrossRefGoogle Scholar
Jahnukainen, K, Salmi, TT, Kristinsson, J, et al. The clinical indications for identical pathogenesis of isolated and non-isolated testicular relapses in acute lymphoblastic leukaemia. Acta Paediatr 1998;87:638–643.CrossRefGoogle ScholarPubMed
Abshire, TC, Buchanan, GR, Jackson, JF, et al. Morphologic, immunologic and cytogenetic studies in children with acute lymphoblastic leukemia at diagnosis and relapse: a Pediatric Oncology Group study. Leukemia 1992;6:357–362.Google ScholarPubMed
Tallen, G, Ratei, R, Mann, G, et al. Long-term outcome in children with relapsed acute lymphoblastic leukemia after time-point and site-of-relapse stratification and intensified short-course multidrug chemotherapy: results of trial ALL-REZ BFM 90. J Clin Oncol 2010;28:2339–2347.CrossRefGoogle ScholarPubMed
Burkhardt, B, Reiter, A, Landmann, E, et al. Poor outcome for children and adolescents with progressive disease or relapse of lymphoblastic lymphoma: a report from the Berlin–Frankfurt–Münster group. J Clin Oncol 2009;27:3363–3369.CrossRefGoogle ScholarPubMed
Meijerink, JP, den Boer, ML, Pieters, R. New genetic abnormalities and treatment response in acute lymphoblastic leukemia. Semin Hematol 2009;46:16–23.CrossRefGoogle ScholarPubMed
Roy, A, Cargill, A, Love, S, et al. Outcome after first relapse in childhood acute lymphoblastic leukaemia: lessons from the United Kingdom R2 trial. Br J Haematol 2005;130:67–75.CrossRefGoogle ScholarPubMed
Fletcher, JA, Lynch, EA, Kimball, VM, et al. Translocation (9;22) is associated with extremely poor prognosis in intensively treated children with acute lymphoblastic leukemia. Blood 1991;77:435–439.Google ScholarPubMed
Schlieben, S, Borkhardt, A, Reinisch, I, et al. Incidence and clinical outcome of children with BCR/ABL-positive acute lymphoblastic leukemia (ALL). A prospective RT-PCR study based on 673 patients enrolled in the German pediatric multicenter therapy trials ALL-BFM-90 and CoALL-05-92. Leukemia 1996;10:957–963.Google ScholarPubMed
Beyermann, B, Adams, HP, Henze, G. Philadelphia chromosome in relapsed childhood acute lymphoblastic leukemia: a matched-pair analysis. Berlin–Frankfurt–Münster Study Group. J Clin Oncol 1997;15:2231–2237.CrossRefGoogle ScholarPubMed
Schultz, KR, Bowman, WP, Aledo, A, et al. Improved early event-free survival with imatinib in Philadelphia chromosome-positive acute lymphoblastic leukemia: a Children's Oncology Group study. J Clin Oncol 2009;27:5175–5181.CrossRefGoogle ScholarPubMed
Borkhardt, A, Cazzaniga, G, Viehmann, S, et al. Incidence and clinical relevance of TEL/AML1 fusion genes in children with acute lymphoblastic leukemia enrolled in the German and Italian multicenter therapy trials. Associazione Italiana Ematologia Oncologia Pediatrica and the Berlin–Frankfurt–Münster Study Group. Blood 1997;90:571–577.Google ScholarPubMed
Rubnitz, JE, Downing, JR, Pui, CH, et al. TEL gene rearrangement in acute lymphoblastic leukemia: a new genetic marker with prognostic significance. J Clin Oncol 1997;15:1150–1157.CrossRefGoogle ScholarPubMed
Loh, ML, Silverman, LB, Young, ML, et al. Incidence of TEL/AML1 fusion in children with relapsed acute lymphoblastic leukemia. Blood 1998;92:4792–4797.Google ScholarPubMed
Rubnitz, JE, Behm, FG, Wichlan, D, et al. Low frequency of TEL-AML1 in relapsed acute lymphoblastic leukemia supports a favorable prognosis for this genetic subgroup. Leukemia 1999;13:19–21.CrossRefGoogle ScholarPubMed
Seeger, K, Adams, HP, Buchwald, D, et al. TEL-AML1 fusion transcript in relapsed childhood acute lymphoblastic leukemia. The Berlin–Frankfurt–Münster Study Group. Blood 1998;91:1716–1722.Google ScholarPubMed
Konrad, M, Metzler, M, Panzer, S, et al. Late relapses evolve from slow-responding subclones in t(12;21)-positive acute lymphoblastic leukemia: evidence for the persistence of a preleukemic clone. Blood 2003;101:3635–3640.CrossRefGoogle Scholar
Zuna, J, Ford, AM, Peham, M, et al. TEL deletion analysis supports a novel view of relapse in childhood acute lymphoblastic leukemia. Clin Cancer Res 2004;10:5355–5360.CrossRefGoogle ScholarPubMed
Seeger, K, Buchwald, D, Peter, A, et al. TEL-AML1 fusion in relapsed childhood acute lymphoblastic leukemia. Blood 1999;94:374–376.Google ScholarPubMed
Henze, G, for Charite University Berlin, Germany. ALL-REZ BFM 2002:Multi-Center Study for Children With Relapsed Acute Lymphoblastic Leukemia [Trial NCT00114348]. Bethesda, MD: National Library of Medicine, 2009 (, accessed January 2012).Google Scholar
Saha, Vfor the Children's Cancer and Leukaemia Group. ALLR3: An International Collaborative Trial for Relapsed and Refractory Acute Lymphoblastic Leukaemia (ALL) [Trial NCT00967057]. Bethesda, MD: National Library of Medicine, 2011 (, accessed January 2012).Google Scholar
Langlands, K, Craig, JI, Anthony, RS, Parker, AC. Clonal selection in acute lymphoblastic leukaemia demonstrated by polymerase chain reaction analysis of immunoglobulin heavy chain and T-cell receptor delta chain rearrangements. Leukemia 1993;7:1066–1070.Google ScholarPubMed
Kawamura, M, Kikuchi, A, Kobayashi, S, et al. Mutations of the p53 and ras genes in childhood t(1;19)-acute lymphoblastic leukemia. Blood 1995;85:2546–2552.Google Scholar
Dhooge, C, De Moerloose, B, Laureys, G, et al. P-glycoprotein is an independent prognostic factor predicting relapse in childhood acute lymphoblastic leukaemia: results of a 6-year prospective study. Br J Haematol 1999;105:676–683.CrossRefGoogle ScholarPubMed
Lam, V, McPherson, JP, Salmena, L, et al. p53 gene status and chemosensitivity of childhood acute lymphoblastic leukemia cells to adriamycin. Leuk Res 1999;23:871–880.CrossRefGoogle ScholarPubMed
Zhou, M, Gu, L, Abshire, TC, et al. Incidence and prognostic significance of MDM2 oncoprotein overexpression in relapsed childhood acute lymphoblastic leukemia. Leukemia 2000;14:61–67.CrossRefGoogle ScholarPubMed
Marks, DI, Kurz, BW, Link, MP, et al. Altered expression of p53 and mdm-2 proteins at diagnosis is associated with early treatment failure in childhood acute lymphoblastic leukemia. J Clin Oncol 1997;15:1158–1162.CrossRefGoogle ScholarPubMed
Blau, O, Avigad, S, Stark, B, et al. Exon 5 mutations in the p53 gene in relapsed childhood acute lymphoblastic leukemia. Leuk Res 1997;21:721–729.CrossRefGoogle ScholarPubMed
Klumper, E, Pieters, R, Veerman, AJ, et al. In vitro cellular drug resistance in children with relapsed/refractory acute lymphoblastic leukemia. Blood 1995;86:3861–3868.Google ScholarPubMed
Kaspers, GJ, Pieters, R, Klumper, E, De, Waal FC, Veerman, AJ. Glucocorticoid resistance in childhood leukemia. Leuk Lymphoma 1994;13:187–201.CrossRefGoogle ScholarPubMed
Cornbleet, MA, Chessells, JM. Bone-marrow relapse in acute lymphoblastic leukaemia in childhood. Br Med J 1978;2:104–106.CrossRefGoogle ScholarPubMed
Creutzig, U, Schellong, G. Treatment of relapse in acute lymphoblastic leukaemia of childhood. Dtsch Med Wochenschr 1980;105:1109–1112.CrossRefGoogle ScholarPubMed
Rivera, G, Pratt, CB, Aur, RJ, Verzosa, M, Hustu, HO. Recurrent childhood lymphocytic leukemia following cessation of therapy: Treatment and response. Cancer 1976;37:1679–1686.3.0.CO;2-8>CrossRefGoogle Scholar
Johnson, FL, Thomas, ED, Clark, BS. A comparison of marrow transplantation with chemotherapy for children with acute lymphoblastic leukemia in second or subsequent remission. N Engl J Med 1981;305:846–851.CrossRefGoogle ScholarPubMed
Woods, WG, Nesbit, ME, Ramsay, NK, et al. Intensive therapy followed by bone marrow transplantation for patients with acute lymphocytic leukemia in second or subsequent remission: Determination of prognostic factors (a report from the University of Minnesota Bone Marrow Transplantation Team). Blood 1983;61:1182–1189.Google Scholar
Lawson, SE, Harrison, G, Richards, S, et al. The UK experience in treating relapsed childhood acute lymphoblastic leukaemia: a report on the medical research council UKALLR1 study. Br J Haematol 2000;108:531–543.CrossRefGoogle ScholarPubMed
Grundy, RG, Leiper, AD, Stanhope, R, Chessells, JM. Survival and endocrine outcome after testicular relapse in acute lymphoblastic leukaemia. Arch Dis Child 1997;76:190–196.CrossRefGoogle ScholarPubMed
Buchanan, GR, Rivera, GK, Pollock, BH, et al. Alternating drug pairs with or without periodic reinduction in children with acute lymphoblastic leukemia in second bone marrow remission: a Pediatric Oncology Group study. Cancer 2000;88:1166–1174.3.0.CO;2-W>CrossRefGoogle ScholarPubMed
Sadowitz, PD, Smith, SD, Shuster, J, et al. Treatment of late bone marrow relapse in children with acute lymphoblastic leukemia: a Pediatric Oncology Group study. Blood 1993;81:602–609.Google ScholarPubMed
Ritchey, AK, Pollock, BH, Lauer, SJ, Andejeski, Y, Buchanan, GR. Improved survival of children with isolated CNS relapse of acute lymphoblastic leukemia: a pediatric oncology group study. J Clin Oncol 1999;17: 3745–3752.CrossRefGoogle ScholarPubMed
Wofford, MM, Smith, SD, Shuster, JJ, et al. Treatment of occult or late overt testicular relapse in children with acute lymphoblastic leukemia: a Pediatric Oncology Group study. J Clin Oncol 1992;10:624–630.CrossRefGoogle ScholarPubMed
Rivera, GK, Hudson, MM, Liu, Q, et al. Effectiveness of intensified rotational combination chemotherapy for late hematologic relapse of childhood acute lymphoblastic leukemia. Blood 1996;88:831–837.Google ScholarPubMed
Giona, F, Testi, AM, Rondelli, R, et al. ALL R-87 protocol in the treatment of children with acute lymphoblastic leukaemia in early bone marrow relapse. Br J Haematol 1997;99:671–677.CrossRefGoogle ScholarPubMed
Henze, G, Fengler, R, Hartmann, R. Chemotherapy for relapsed childhood acute lymphoblastic leukemia: results of the BFM Study Group. Haematol Blood Transfus 1994;36:374–379.Google Scholar
Morland, BJ, Shaw, PJ. Induction toxicity of a modified Memorial Sloan-Kettering-New York II Protocol in children with relapsed acute lymphoblastic leukemia: a single institution study. Med Pediatr Oncol 1996;27:139–144.3.0.CO;2-F>CrossRefGoogle ScholarPubMed
Einsiedel, HG, von Stackelberg, A, Hartmann, R, et al. Long-term outcome in children with relapsed ALL by risk-stratified salvage therapy: results of trial acute lymphoblastic leukemia-relapse study of the Berlin–Frankfurt–Münster Group 87. J Clin Oncol 2005;23:7942–7950.CrossRefGoogle ScholarPubMed
Raetz, EA, Borowitz, MJ, Devidas, M, et al. Reinduction platform for children with first marrow relapse of acute lymphoblastic leukemia: a Children's Oncology Group Study [corrected]. J Clin Oncol 2008;26:3971–3978.CrossRefGoogle Scholar
Buchanan, GR, Rivera, GK, Boyett, JM, et al. Reinduction therapy in 297 children with acute lymphoblastic leukemia in first bone marrow relapse: a Pediatric Oncology Group study. Blood 1988;72:1286–1292.Google ScholarPubMed
Hryniuk, WM.The importance of dose intensity in the outcome of chemotherapy. Important Adv Oncol 1988:121–141.Google ScholarPubMed
Herold, R, von Stackelberg, A, Hartmann, R, Eisenreich, B, Henze, G. Acute Lymphoblastic Leukemia- Relapse Study of the Berlin–Frankfurt–Münster (ALL-REZ BFM) experience: early treatment intensity makes the difference. J Clin Oncol 2004;22:569–570.CrossRefGoogle ScholarPubMed
Bernstein, ML, Abshire, TC, Pollock, BH, et al. Idarubicin and cytosine arabinoside reinduction therapy for children with multiple recurrent or refractory acute lymphoblastic leukemia: a Pediatric Oncology Group study. J Pediatr Hematol Oncol 1997;19:68–72.CrossRefGoogle ScholarPubMed
Fleischhack, G, Hasan, C, Graf, N, Mann, G, Bode, U. IDA-FLAG (idarubicin, fludarabine, cytarabine, G-CSF), an effective remission-induction therapy for poor-prognosis AML of childhood prior to allogeneic or autologous bone marrow transplantation: experiences of a phase II trial. Br J Haematol 1998;102:647–655.CrossRefGoogle ScholarPubMed
Hijiya, N, Gaynon, PS, Fernandez, M, et al. Durable remissions observed in a phase I/II study of clofarabine in combination with etoposide and cyclophosphamide in pediatric patients with refractory or relapsed acute leukemia. Blood 2008;112:2925.Google Scholar
Horstmann, MA, Hassenpflug, WA, zur Stadt, U, et al. Amsacrine combined with etoposide and high-dose methylprednisolone as salvage therapy in acute lymphoblastic leukemia in children. Haematologica 2005;90:1701–1703.Google ScholarPubMed
Testi, AM, Del Giudice, I, Arcese, W, et al. A single high dose of idarubicin combined with high-dose ARA-C for treatment of first relapse in childhood ‘high-risk’ acute lymphoblastic leukaemia: a study of the AIEOP group. Br J Haematol 2002;118:741–747.CrossRefGoogle ScholarPubMed
von Stackelberg, A, Hartmann, R, Buhrer, C, et al. High-dose compared with intermediate-dose methotrexate in children with a first relapse of acute lymphoblastic leukemia. Blood 2008;111:2573–2580.CrossRefGoogle Scholar
Buehrer, C, Hartmann, R, Fengler, R, et al. Importance of effective central nervous system therapy in isolated bone marrow relapse of childhood acute lymphoblastic leukemia. Blood 1994;83:3468–3472.Google Scholar
Land, VJ, Thomas, PR, Boyett, JM, et al. Comparison of maintenance treatment regimens for first central nervous system relapse in children with acute lymphocytic leukemia. A Pediatric Oncology Group study. Cancer 1985;56:81–87.3.0.CO;2-2>CrossRefGoogle ScholarPubMed
Barredo, JC, Devidas, M, Lauer, SJ, et al. Isolated CNS relapse of acute lymphoblastic leukemia treated with intensive systemic chemotherapy and delayed CNS radiation: a pediatric oncology group study. J Clin Oncol 2006;24:3142–3149.CrossRefGoogle ScholarPubMed
Domenech, C, Mercier, M, Plouvier, E, et al. First isolated extramedullary relapse in children with B-cell precursor acute lymphoblastic leukaemia: results of the Cooprall-97 study. Eur J Cancer 2008;44:2461–2469.CrossRefGoogle ScholarPubMed
Krishnan, S, Wade, R, Moorman, AV, et al. Temporal changes in the incidence and pattern of central nervous system relapses in children with acute lymphoblastic leukaemia treated on four consecutive Medical Research Council trials, 1985–2001. Leukemia 2010;24:450–459.CrossRefGoogle ScholarPubMed
von Stackelberg, A, Harms, D, Klingebiel, T, et al. Gender and age at initial diagnosis are independent prognostic factors in childhood isolated CNS relapse. Med Pediatr Oncol 2002;39: 277.Google Scholar
Hertzberg, H, Huk, WJ, Ueberall, MA, et al. CNS late effects after ALL therapy in childhood. Part I: Neuroradiological findings in long-term survivors of childhood ALL: an evaluation of the interferences between morphology and neuropsychological performance. The German Late Effects Working Group. Med Pediatr Oncol 1997;28:387–400.3.0.CO;2-C>CrossRefGoogle ScholarPubMed
Messina, C, Valsecchi, MG, Arico, M, et al. Autologous bone marrow transplantation for treatment of isolated central nervous system relapse of childhood acute lymphoblastic leukemia. AIEOP/FONOP-TMO Group. Associzione Italiana Emato-Oncologia Pediatrica. Bone Marrow Transplant 1998;21:9–14.CrossRefGoogle Scholar
Eapen, M, Zhang, MJ, Devidas, M, et al. Outcomes after HLA-matched sibling transplantation or chemotherapy in children with acute lymphoblastic leukemia in a second remission after an isolated central nervous system relapse: a collaborative study of the Children's Oncology Group and the Center for International Blood and Marrow Transplant Research. Leukemia 2008;22:281–286.CrossRefGoogle ScholarPubMed
Goulden, N, Langlands, K, Steward, C, et al. PCR assessment of bone marrow status in ‘isolated' extramedullary relapse of childhood B-precursor acute lymphoblastic leukaemia. Br J Haematol 1994;87:282–285.CrossRefGoogle ScholarPubMed
Nachman, J, Palmer, NF, Sather, HN, et al. Open-wedge testicular biopsy in childhood acute lymphoblastic leukemia after two years of maintenance therapy: diagnostic accuracy and influence on outcome: a report from Children's Cancer Study Group. Blood 1990;75: 1051–1055.Google ScholarPubMed
Uderzo, C, Grazia, Zurlo M, Adamoli, L, et al. Treatment of isolated testicular relapse in childhood acute lymphoblastic leukemia: an Italian multicenter study. J Clin Oncol 1990;8:672–677.CrossRefGoogle Scholar
Castillo, LA, Craft, AW, Kernahan, J, Evans, RG, Aynsley-Green, A. Gonadal function after 12-Gy testicular irradiation in childhood acute lymphoblastic leukaemia. Med Pediatr Oncol 1990;18:185–189.CrossRefGoogle ScholarPubMed
Leiper, AD, Grant, DB, Chessells, JM. Gonadal function after testicular radiation for acute lymphoblastic leukaemia. Arch Dis Child 1986;61:53–56.CrossRefGoogle ScholarPubMed
von Stackelberg, A, Tabien, U, van Schewick, C, et al. Bilateral involvement is an important prognostic factor in isolated testicular relapse of childhood ALL. Pediatr Blood Cancer Suppl 2008:28.Google Scholar
Askin, FB, Land, VJ, Sullivan, MP, et al. Occult testicular leukemia: Testicular biopsy at three years continuous complete remission of childhood leukemia: a Southwest Oncology Group study. Cancer 1981;47:470–475.3.0.CO;2-T>CrossRefGoogle ScholarPubMed
Ortega, JJ, Javier, G, Toran, N. Testicular infiltrates in children with acute lymphoblastic leukemia: a prospective study. Med Pediatr Oncol 1984;12:386–393.CrossRefGoogle ScholarPubMed
Bader, P, Hancock, J, Kreyenberg, H, et al. Minimal residual disease (MRD) status prior to allogeneic stem cell transplantation is a powerful predictor for post-transplant outcome in children with ALL. Leukemia 2002;16:1668–1672.CrossRefGoogle Scholar
Bader, P, Kreyenberg, H, Henze, GH, et al. Prognostic value of minimal residual disease quantification before allogeneic stem-cell transplantation in relapsed childhood acute lymphoblastic leukemia: the ALL-REZ BFM Study Group. J Clin Oncol 2009;27:377–384.CrossRefGoogle ScholarPubMed
Knechtli, CJ, Goulden, NJ, Hancock, JP, et al. Minimal residual disease status before allogeneic bone marrow transplantation is an important determinant of successful outcome for children and adolescents with acute lymphoblastic leukemia. Blood 1998;92:4072–4079.Google ScholarPubMed
Bader, P, Beck, J, Frey, A, et al. Serial and quantitative analysis of mixed hematopoietic chimerism by PCR in patients with acute leukemias allows the prediction of relapse after allogeneic BMT. Bone Marrow Transplant 1998;21:487–495.CrossRefGoogle ScholarPubMed
Bader, P, Klingebiel, T, Schaudt, A, et al. Prevention of relapse in pediatric patients with acute leukemias and MDS after allogeneic SCT by early immunotherapy initiated on the basis of increasing mixed chimerism: a single center experience of 12 children. Leukemia 1999;13:2079–2086.CrossRefGoogle ScholarPubMed
Bader, P, Kreyenberg, H, Henze, G, et al. Predictive value of MRD monitoring after allogeneic SCT in relapsed childhood acute lymphoblastic leukaemia: analysis of the ALL-REZ BFM Group (abstract). Bone Marrow Transplant 2009;43(Suppl 1):40.Google Scholar
Borgmann, A, Baumgarten, E, Schmid, H, et al. Allogeneic bone marrow transplantation for a subset of children with acute lymphoblastic leukemia in third remission: a conceivable alternative? Bone Marrow Transplant 1997;20:939–944.CrossRefGoogle ScholarPubMed
Storb, R, Bryant, JI, Buckner, CD, et al. Allogeneic marrow grafting for acute lymphoblastic leukemia: Leukemic relapse. Transplant Proc 1973;5:923–926.Google ScholarPubMed
Thomas, ED, Buckner, CD, Banaji, M, et al. One hundred patients with acute leukemia treated by chemotherapy, total body irradiation, and allogeneic marrow transplantation. Blood 1977;49:511–533.Google ScholarPubMed
Brochstein, JA, Kernan, NA, Groshen, S, et al. Allogeneic bone marrow transplantation after hyperfractionated total-body irradiation and cyclophosphamide in children with acute leukemia. N Engl J Med 1987;317:1618–1624.CrossRefGoogle ScholarPubMed
Moussalem, M, Esperou Bourdeau, H, Devergie, A, et al. Allogeneic bone marrow transplantation for childhood acute lymphoblastic leukemia in second remission: factors predictive of survival, relapse and graft-versus-host disease. Bone Marrow Transplant 1995;15:943–947.Google ScholarPubMed
Uderzo, C, Rondelli, R, Dini, G, et al. High-dose vincristine, fractionated total-body irradiation and cyclophosphamide as conditioning regimen in allogeneic and autologous bone marrow transplantation for childhood acute lymphoblastic leukaemia in second remission: a 7-year Italian multicentre study. Br J Haematol 1995;89:790–797.CrossRefGoogle ScholarPubMed
Weyman, C, Graham-Pole, J, Emerson, S, et al. Use of cytosine arabinoside and total body irradiation as conditioning for allogeneic marrow transplantation in patients with acute lymphoblastic leukemia: a multicenter survey. Bone Marrow Transplant 1993;11:43–50.Google ScholarPubMed
Dopfer, R, Henze, G, Bender-Götze, C, et al. Allogeneic bone marrow transplantation for childhood acute lymphoblastic leukemia in second remission after intensive primary and relapse therapy according to the BFM- and CoALL-protocols: results of the German Cooperative Study. Blood 1991;78:2780–2784.Google ScholarPubMed
Bunin, N, Aplenc, R, Kamani, N, et al. Randomized trial of busulfan vs total body irradiation containing conditioning regimens for children with acute lymphoblastic leukemia: a Pediatric Blood and Marrow Transplant Consortium study. Bone Marrow Transplant 2003;32:543–548.CrossRefGoogle ScholarPubMed
Barrett, AJ, Horowitz, MM, Pollock, BH, et al. Bone marrow transplants from HLA-identical siblings as compared with chemotherapy for children with acute lymphoblastic leukemia in a second remission. N Engl J Med 1994;331:1253–1258.CrossRefGoogle Scholar
Beatty, PG, Hansen, JA, Longton, GM, et al. Marrow transplantation from HLA-matched unrelated donors for treatment of hematologic malignancies. Transplantation 1991;51:443–447.CrossRefGoogle ScholarPubMed
Kernan, NA, Bartsch, G, Ash, RC, et al. Analysis of 462 transplantations from unrelated donors facilitated by the National Marrow Donor Program. N Engl J Med 1993;328:593–602.CrossRefGoogle ScholarPubMed
Oakhill, A, Pamphilon, DH, Potter, MN, et al. Unrelated donor bone marrow transplantation for children with relapsed acute lymphoblastic leukaemia in second complete remission. Br J Haematol 1996;94:574–578.CrossRefGoogle ScholarPubMed
Lausen, BF, Heilmann, C, Vindelov, L, Jacobsen, N. Outcome of acute lymphoblastic leukaemia in Danish children after allogeneic bone marrow transplantation. Superior survival following transplantation with matched unrelated donor grafts. Bone Marrow Transplant 1998;22:325–330.CrossRefGoogle ScholarPubMed
Borgmann, A, von Stackelberg, A, Hartmann, R, et al. Unrelated donor stem cell transplantation compared with chemotherapy for children with acute lymphoblastic leukemia in a second remission: a matched-pair analysis. Blood 2003;101:3835–3839.CrossRefGoogle Scholar
Schrauder, A, von Stackelberg, A, Schrappe, M, Cornish, J, Peters, C. Allogeneic hematopoietic SCT in children with ALL: current concepts of ongoing prospective SCT trials. Bone Marrow Transplant 2008;41(Suppl 2): S71–S74.CrossRefGoogle ScholarPubMed
Kawano, Y, Takaue, Y, Watanabe, A, et al. Partially mismatched pediatric transplants with allogeneic CD34(+) blood cells from a related donor. Blood 1998;92:3123–3130.Google ScholarPubMed
Szydlo, R, Goldman, JM, Klein, JP, et al. Results of allogeneic bone marrow transplants for leukemia using donors other than HLA-identical siblings. J Clin Oncol 1997;15:1767–1777.CrossRefGoogle ScholarPubMed
Peters, C, Schrauder, A, Schrappe, M, et al. Allogeneic haematopoietic stem cell transplantation in children with acute lymphoblastic leukaemia: the BFM/IBFM/EBMT concepts. Bone Marrow Transplant 2005;35(Suppl 1): S9–S11.CrossRefGoogle ScholarPubMed
Aversa, F, Tabilio, A, Velardi, A, et al. Treatment of high-risk acute leukemia with T-cell-depleted stem cells from related donors with one fully mismatched HLA haplotype. N Engl J Med 1998;339:1186–1193.CrossRefGoogle ScholarPubMed
Klingebiel, T, Cornish, J, Labopin, M, et al. Results and factors influencing outcome after fully haploidentical hematopoietic stem cell transplantation in children with very high-risk acute lymphoblastic leukemia: impact of center size: an analysis on behalf of the Acute Leukemia and Pediatric Disease Working Parties of the European Blood and Marrow Transplant group. Blood 2010;115:3437–3446.CrossRefGoogle Scholar
Locatelli, F, Rocha, V, Chastang, C, et al. Factors associated with outcome after cord blood transplantation in children with acute leukemia. Eurocord-Cord Blood Transplant Group. Blood 1999;93:3662–3671.Google ScholarPubMed
Slavin, S, Nagler, A, Naparstek, E, et al. Nonmyeloablative stem cell transplantation and cell therapy as an alternative to conventional bone marrow transplantation with lethal cytoreduction for the treatment of malignant and nonmalignant hematologic diseases. Blood 1998;91:756–763.Google Scholar
Messina, C, Cesaro, S, Rondelli, R, et al. Autologous bone marrow transplantation for childhood acute lymphoblastic leukaemia in Italy. AIEOP/FONOP-TMO Group. Italian Association of Paediatric Haemato-Oncology. Bone Marrow Transplant 1998;21:1015–1021.CrossRefGoogle Scholar
Borgmann, A, von Stackelberg, A, Baumgarten, E, et al. Immunotherapy of acute lymphoblastic leukemia by vaccination with autologous leukemic cells transfected with a cDNA expression plasmid coding for an allogeneic HLA class I antigen combined with interleukin-2 treatment. J Mol Med 1998;76(3–4): 215–221.Google ScholarPubMed
Weisdorf, DJ, Billett, AL, Hannan, P, et al. Autologous versus unrelated donor allogeneic marrow transplantation for acute lymphoblastic leukemia. Blood 1997;90:2962–2968.Google ScholarPubMed
Borgmann, A, Schmid, H, Hartmann, R, et al. Autologous bone-marrow transplants compared with chemotherapy for children with acute lymphoblastic leukaemia in a second remission: a matched-pair analysis. The Berlin–Frankfurt–Münster Study Group. Lancet 1995;346:873–876.CrossRefGoogle Scholar
Balduzzi, A, Bonanomi, S, Valsecchi, MG, et al. Autologous purified peripheral blood SCT in childhood low-risk relapsed ALL. Bone Marrow Transplant 2011;46:217–226.CrossRefGoogle ScholarPubMed
Pui, CH, Jeha, S. New therapeutic strategies for the treatment of acute lymphoblastic leukaemia. Nat Rev Drug Discov 2007;6:149–165.CrossRefGoogle Scholar
Jeha, S, Gaynon, PS, Razzouk, BI, et al. Phase II study of clofarabine in pediatric patients with refractory or relapsed acute lymphoblastic leukemia. J Clin Oncol 2006;24:1917–1923.CrossRefGoogle ScholarPubMed
Kearns, P, Michel, G, Nelken, B, et al. A European phase II study (BIOV-111) of clofarabine (Evoltra(R)) in refractory and relapsed childhood acute lymphoblastic leukemia: final results. Blood 2007;110:11a.Google Scholar
Berg, SL, Blaney, SM, Devidas, M, et al. Phase II study of nelarabine (compound 506U78) in children and young adults with refractory T-cell malignancies: a report from the Children's Oncology Group. J Clin Oncol 2005;23:3376–3382.CrossRefGoogle Scholar
Locatelli, F, Testi, AM, Bernardo, ME, et al. Clofarabine, cyclophosphamide and etoposide as single-course re-induction therapy for children with refractory/multiple relapsed acute lymphoblastic leukaemia. Br J Haematol 2009;147:371–378.CrossRefGoogle ScholarPubMed
Hijiya, N, Gaynon, P, Barry, E, et al. A multi-center phase I study of clofarabine, etoposide and cyclophosphamide in combination in pediatric patients with refractory or relapsed acute leukemia. Leukemia 2009;23:2259–2264.CrossRefGoogle ScholarPubMed
Steinherz, PG, Shukla, N, Kobos, R, Steinherz, L. Remission re-induction chemotherapy with clofarabine, topotecan, thiotepa, and vinorelbine for patients with relapsed or refractory leukemia. Pediatr Blood Cancer 2010;54:687–693.CrossRefGoogle ScholarPubMed
Mundipharma-Research Ltd. Pharmacokinetic Study of Forodesine in Children With Relapsed or Refractory T-cell or B-cell Precursor Acute Lymphoblastic Leukaemia or T-cell Non- Hodgkin's Lymphoma. (BCX1777–108) [Trial NCT00742495, now terminated]. Bethesda, MD: National Library of Medicine, 2011 (, accessed January 2012).Google Scholar
Zwaan, CM, Rizzari, C, van der Velden, VHJ, et al. Dasatinib in children and adolescents with relapsed or refractory leukemia: interim results of the CA180–018 phase I study from the ITCC Consortium. Blood 2008;112: 3241a.Google Scholar
Kantarjian, H, Giles, F, Wunderle, L, et al. Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL. N Engl J Med 2006;354:2542–2551.CrossRefGoogle ScholarPubMed
Horton, TM, Pati, D, Plon, SE, et al. A phase 1 study of the proteasome inhibitor bortezomib in pediatric patients with refractory leukemia: a Children's Oncology Group study. Clin Cancer Res 2007;13:1516–1522.CrossRefGoogle ScholarPubMed
Teachey, DT, Grupp, SA, Brown, VI. Mammalian target of rapamycin inhibitors and their potential role in therapy in leukaemia and other haematological malignancies. Br J Haematol 2009;145:569–580.CrossRefGoogle ScholarPubMed
Bonapace, L, Bornhauser, BC, Schmitz, M, et al. Induction of autophagy-dependent necroptosis is required for childhood acute lymphoblastic leukemia cells to overcome glucocorticoid resistance. J Clin Invest 2010;120:1310–1323.CrossRefGoogle ScholarPubMed
Schimmer, AD, O'Brien, S, Kantarjian, H, et al. A phase I study of the pan bcl-2 family inhibitor obatoclax mesylate in patients with advanced hematologic malignancies. Clin Cancer Res 2008;14:8295–8301.CrossRefGoogle ScholarPubMed
Coiffier, B, Lepage, E, Briere, J, et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med 2002;346:235–242.CrossRefGoogle ScholarPubMed
Claviez, A, Eckert, C, Seeger, K, et al. Rituximab plus chemotherapy in children with relapsed or refractory CD20-positive B-cell precursor acute lymphoblastic leukemia. Haematologica 2006;91:272–273.Google ScholarPubMed
Horton, HM, Bernett, MJ, Pong, E, et al. Potent in vitro and in vivo activity of an Fc-engineered anti-CD19 monoclonal antibody against lymphoma and leukemia. Cancer Res 2008;68:8049–8057.CrossRefGoogle ScholarPubMed
Topp, M, Goekbuget, N, Kufer, P, et al. Treatment with anti-CD19 BiTE antibody blinatumomab (MT103/MEDI-538) is able to eliminate minimal residual disease (MRD) in patients with B-precursor acute lymphoblastic leukemia (ALL): first results of an ongoing phase II study. Blood 2008;112:1926a.Google Scholar
Bargou, R, Leo, E, Zugmaier, G, et al. Tumor regression in cancer patients by very low doses of a T cell-engaging antibody. Science 2008;321:974–977.CrossRefGoogle ScholarPubMed
Leonard, JP, Coleman, M, Ketas, JC, et al. Epratuzumab, a humanized anti-CD22 antibody, in aggressive non-Hodgkin's lymphoma: phase I/II clinical trial results. Clin Cancer Res 2004;10:5327–5334.CrossRefGoogle ScholarPubMed
Raetz, EA, Cairo, MS, Borowitz, MJ, et al. Chemoimmunotherapy reinduction with epratuzumab in children with acute lymphoblastic leukemia in marrow relapse: a Children's Oncology Group Pilot Study. J Clin Oncol 2008;26:3756–3762.CrossRefGoogle ScholarPubMed
DiJoseph, JF, Dougher, MM, Armellino, DC, Evans, DY, Damle, NK. Therapeutic potential of CD22-specific antibody-targeted chemotherapy using inotuzumab ozogamicin (CMC-544) for the treatment of acute lymphoblastic leukemia. Leukemia 2007;21:2240–2245.CrossRefGoogle ScholarPubMed
Alderson, RF, Kreitman, RJ, Chen, T, et al. CAT-8015: a second-generation pseudomonas exotoxin A-based immunotherapy targeting CD22-expressing hematologic malignancies. Clin Cancer Res 2009;15:832–839.CrossRefGoogle ScholarPubMed

Save book to Kindle

To save this book to your Kindle, first ensure coreplatform@cambridge.org is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about saving to your Kindle.

Note you can select to save to either the @free.kindle.com or @kindle.com variations. ‘@free.kindle.com’ emails are free but can only be saved to your device when it is connected to wi-fi. ‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

Find out more about the Kindle Personal Document Service.

Available formats
×

Save book to Dropbox

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Dropbox.

Available formats
×

Save book to Google Drive

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Google Drive.

Available formats
×